GENSCRIPT BIO (01548) saw its afternoon losses widen by more than 11%, falling 11.07% to HK$13.41 by the time of writing, with a turnover of HK$307 million. The decline follows an overnight drop of over 7% in its affiliate Legend Biotech (LEGN). Reports indicate that at the 2025 American Society of Hematology (ASH) annual meeting, Kite Pharma, a subsidiary of Gilead Sciences, unveiled updated clinical data for its next-generation CAR-T therapy, anito-cel. The candidate drug for multiple myeloma demonstrated a 96% overall response rate and a 74% complete response rate while maintaining strong safety.

Huatai Securities previously noted that Legend Biotech has narrowed its losses, with a clearer strategic roadmap. CARVYKTI generated sales of $1.332 billion in the first three quarters, including $524 million in Q3. Legend Biotech reported a net loss of $266 million for the first nine months, with Q3 losses shrinking to $40 million, marking significant year-on-year and sequential improvements. The firm remains optimistic about GENSCRIPT BIO's orderly profit growth and turnaround across its business segments.